OrphAI Therapeutics

Focus: OrphAI Therapeutics is an AI-focused oncology biotech based in New Haven, CT, leveraging artificial intelligence to develop cancer therapeutics. The company operates as a pre-revenue or early-stage biotech with a diversified pipeline spanning oncology, neurology, and rare pulmonary diseases.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About OrphAI Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow OrphAI Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

LAM-002A

Frontotemporal Dementia

N/A

Clinical Trials (1)

NCT05483322An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)

N/A

Help build intelligence for OrphAI Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at an AI-native oncology company with potential to shape next-generation drug discovery at the intersection of machine learning and cancer biology
Diversified pipeline of 7 active programs across multiple therapeutic areas (oncology, neurology, pulmonary disease) provides cross-functional learning and reduced single-asset risk
Located in New Haven's biotech hub with access to Yale talent and infrastructure, offering academic collaboration opportunities

Watch Out For

Zero active job postings signal company may not be actively hiring or is in a consolidation/financing phase, creating limited entry points
No disclosed funding, revenue, or employee count data raises uncertainty about financial stability, runway, and organizational scale
Early-stage pipeline (2 Phase 1, 4 Phase 2, 0 Phase 3 programs) means no near-term commercial catalysts or revenue events for 3-5+ years

Generated by Claude from OrphAI Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Open Label LAM-003

Oncology

Phase 1

Clinical Trials (1)

NCT03426605A Study of LAM-003 in Patients With Acute Myeloid Leukemia

Phase 1

LAM-002A

Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic

Phase 1

Clinical Trials (1)

NCT02594384A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma

Phase 1